Performance of [18F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy
(2023) In Parkinsonism and Related Disorders 106.- Abstract
Introduction: The diagnosis of progressive supranuclear palsy (PSP) is often challenging since PSP may clinically resemble other neurodegenerative disorders. Recently, the tau PET tracer [18F]RO948, a potential new biomarker for PSP, was developed. The aim of this study was to determine the ability of three different biomarkers, including [18F]RO948 PET, to distinguish PSP patients from healthy controls and from patients with α-synucleinopathies. Methods: Patients with PSP (n = 23), α-synucleinopathies (n = 47) and healthy controls (n = 61) were included from the BioFINDER-2 study. [18F]RO948 standardized uptake value ratios (SUVR), magnetic resonance imaging midbrain/pons ratio, and cerebrospinal fluid... (More)
Introduction: The diagnosis of progressive supranuclear palsy (PSP) is often challenging since PSP may clinically resemble other neurodegenerative disorders. Recently, the tau PET tracer [18F]RO948, a potential new biomarker for PSP, was developed. The aim of this study was to determine the ability of three different biomarkers, including [18F]RO948 PET, to distinguish PSP patients from healthy controls and from patients with α-synucleinopathies. Methods: Patients with PSP (n = 23), α-synucleinopathies (n = 47) and healthy controls (n = 61) were included from the BioFINDER-2 study. [18F]RO948 standardized uptake value ratios (SUVR), magnetic resonance imaging midbrain/pons ratio, and cerebrospinal fluid neurofilament light (NfL) levels were compared between diagnostic groups individually and in combination. Results: [18F]RO948 PET SUVR in the globus pallidus, NfL, and midbrain/pons area ratios were all able to differentiate PSP patients from controls and from patients with α-synucleinopathies ([18F]RO948 [mean ± SD]: controls 1.24 ± 0.22; PSP 1.47 ± 0.4; PD 1.18 ± 0.2; DLB 1.25 ± 0.24, p < 0.05), (NfL pg/mL [mean ± SD]: controls 1055 ± 569; PSP 2197 ± 1010; PD 1038 ± 416; DLB 1548 ± 687, p < 0.001) and (midbrain/pons ratio [mean ± SD]: controls 0.46 ± 0.07; PSP 0.34 ± 0.09; PD 0.43 ± 0.06; DLB 0.40 ± 0.07, p < 0.01). Receiver operating characteristic (ROC) analyses indicated that combining the three biomarkers resulted in the highest area under the ROC values (0.94 [0.88–1.00]) for separating controls from PSP and (0.92 [0.85–0.99]) for separating PSP from α-synucleinopathies. Conclusions: All studied biomarkers could individually separate PSP from controls and α-synucleinopathies patients at a group level. The optimal prediction models included NfL and midbrain/pons ratio for separating controls from PSP and all three biomarkers for separating PSP from α-synucleinopathies.
(Less)
- author
- Oliveira Hauer, Kevin LU ; Pawlik, Daria LU ; Leuzy, Antoine LU ; Janelidze, Shorena LU ; Hall, Sara LU ; Hansson, Oskar LU and Smith, Ruben LU
- organization
- publishing date
- 2023-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Parkinsonism and Related Disorders
- volume
- 106
- article number
- 105226
- publisher
- Elsevier
- external identifiers
-
- pmid:36442367
- scopus:85142699408
- ISSN
- 1353-8020
- DOI
- 10.1016/j.parkreldis.2022.11.018
- language
- English
- LU publication?
- yes
- id
- ee24174a-e336-466e-84c5-1b077f2d5faa
- date added to LUP
- 2023-01-31 15:05:55
- date last changed
- 2024-09-17 10:57:09
@article{ee24174a-e336-466e-84c5-1b077f2d5faa, abstract = {{<p>Introduction: The diagnosis of progressive supranuclear palsy (PSP) is often challenging since PSP may clinically resemble other neurodegenerative disorders. Recently, the tau PET tracer [<sup>18</sup>F]RO948, a potential new biomarker for PSP, was developed. The aim of this study was to determine the ability of three different biomarkers, including [<sup>18</sup>F]RO948 PET, to distinguish PSP patients from healthy controls and from patients with α-synucleinopathies. Methods: Patients with PSP (n = 23), α-synucleinopathies (n = 47) and healthy controls (n = 61) were included from the BioFINDER-2 study. [<sup>18</sup>F]RO948 standardized uptake value ratios (SUVR), magnetic resonance imaging midbrain/pons ratio, and cerebrospinal fluid neurofilament light (NfL) levels were compared between diagnostic groups individually and in combination. Results: [<sup>18</sup>F]RO948 PET SUVR in the globus pallidus, NfL, and midbrain/pons area ratios were all able to differentiate PSP patients from controls and from patients with α-synucleinopathies ([<sup>18</sup>F]RO948 [mean ± SD]: controls 1.24 ± 0.22; PSP 1.47 ± 0.4; PD 1.18 ± 0.2; DLB 1.25 ± 0.24, p < 0.05), (NfL pg/mL [mean ± SD]: controls 1055 ± 569; PSP 2197 ± 1010; PD 1038 ± 416; DLB 1548 ± 687, p < 0.001) and (midbrain/pons ratio [mean ± SD]: controls 0.46 ± 0.07; PSP 0.34 ± 0.09; PD 0.43 ± 0.06; DLB 0.40 ± 0.07, p < 0.01). Receiver operating characteristic (ROC) analyses indicated that combining the three biomarkers resulted in the highest area under the ROC values (0.94 [0.88–1.00]) for separating controls from PSP and (0.92 [0.85–0.99]) for separating PSP from α-synucleinopathies. Conclusions: All studied biomarkers could individually separate PSP from controls and α-synucleinopathies patients at a group level. The optimal prediction models included NfL and midbrain/pons ratio for separating controls from PSP and all three biomarkers for separating PSP from α-synucleinopathies.</p>}}, author = {{Oliveira Hauer, Kevin and Pawlik, Daria and Leuzy, Antoine and Janelidze, Shorena and Hall, Sara and Hansson, Oskar and Smith, Ruben}}, issn = {{1353-8020}}, language = {{eng}}, publisher = {{Elsevier}}, series = {{Parkinsonism and Related Disorders}}, title = {{Performance of [<sup>18</sup>F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy}}, url = {{http://dx.doi.org/10.1016/j.parkreldis.2022.11.018}}, doi = {{10.1016/j.parkreldis.2022.11.018}}, volume = {{106}}, year = {{2023}}, }